在Omicron期间对COVID-19和新生儿结果的孕产妇疫苗接种:INTERCOVID-2022研究
Fernando C Barros1, Robert B Gunier2, Albertina Rego3
1Post Graduate Program in Health in the Life Cycle, Universidade Católica de Pelotas, Pelotas, Brazil.
American journal of obstetrics and gynecology
|February 17, 2024
概括
孕产妇COVID-19疫苗接种,特别是增剂,在Omicron变异激增期间显著减少新生儿并发症和死亡. 当母亲在分娩后14周内接种疫苗或强剂时,可以实现对新生儿的最佳保护.
科学领域:
- 产科和妇科 产科和妇科
- 新生儿科学 新生儿科学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 以前的研究表明,接种孕妇疫苗可以减少在Omicron变种激增期间的严重COVID-19并发症.
- 这项研究侧重于COVID-19对新生儿的影响以及怀孕期间母亲接种疫苗的有效性.
研究的目的:
- 分析COVID-19在怀孕期间对新生儿结果的影响.
- 为了评估母婴COVID-19疫苗接种对新生儿的影响,当时Omicron是主要的变种.
主要方法:
- 一项大型的前性观察性研究 (INTERCOVID-2022),涉及18个国家的40家医院.
- 在怀孕期间与没有COVID-19的母亲出生的新生儿的比较,随访直到出院.
- 疫苗有效性的评估,根据母亲的风险概况进行调整,主要结果包括新生儿COVID-19阳性,发病率和死亡率.
主要成果:
- 与未接种疫苗的母亲相比,接种了COVID-19增剂疫苗的母亲所产生的新生儿的COVID-19阳性测试风险不到一半.
- 补充疫苗接种与早产,呼吸困扰综合征和新生儿重症监护室 (NICU) 的最低比率有关.
- 与未接种疫苗的母亲相比,未接种疫苗的母亲的新生儿面临新生儿死亡风险的两倍;接种疫苗并没有增加先天性形.
- 疫苗对新生儿COVID-19阳性反应的有效性在增强剂 (64%) 中最高,但对中度/重度新生儿结果的有效性较低 (13-28%).
结论:
- 孕产妇COVID-19疫苗接种,特别是强剂,对于在Omicron变种期间减少新生儿发病率和死亡率至关重要.
- 未接种疫苗的母亲的新生儿经历了新生儿死亡和不良结果的风险增加.
- 为了最大限度地保护新生儿,孕妇应在预期分娩日后14周内接种COVID-19疫苗或强剂,因为疫苗的保护随着时间的推移而减弱.
关键词:
在 COVID-19 疫情中,接种COVID-19疫苗的时间这就是SARS-CoV-2病毒.暴露于SARS-CoV-2病毒的情况.疾病发病率 疾病发病率 疾病发病率死亡率 死亡率多中心研究多中心研究.新生儿健康新生儿健康新生儿重症监护室入院新生儿的结果.神经学结果的神经学结果.新生儿新生儿的新生儿围产期的实践 围产期的做法怀孕 怀孕 怀孕 怀孕 怀孕过早出生 过早出生呼吸系统支持呼吸系统的支持呼吸道症状 呼吸道症状皮肤对皮肤的接触更多相关视频
13:00Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
3.6K
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
10.4K
相关概念视频
01:51Vaccinations
44.5K
Overview
44.5K
01:22Development of Immunocompetence
307
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
307
01:07Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
01:22Healthcare Associated Infections II: Preventive Measures
2.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.6K